GlassScriptPhysician profile
Eric M Reiman
NPI 1013976059
$157,284.21
in general payments reported to CMS, 2019-2025
11 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $3,480 · 2021: $143K · 2022: $309 · 2024: $161 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $488 · Food and Beverage: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $487.50 |
| Food and Beverage | $160.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols, S.A. | $142,586.55 | 2021 | |
| F. Hoffmann-La Roche Ag | $10,132.20 | 2019 | |
| Biogen, INC. | $3,480.00 | 2020 | |
| Glaxosmithkline, LLC. | $487.50 | 2025 | |
| Eli Lilly and Company | $158.77 | 2022 | |
| Genentech USA, INC. | $149.86 | 2022 | |
| Roche Molecular Systems, INC. | $143.04 | 2024 | |
| Roche Products Limited | $103.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.45 | 2019 | |
| Lilly USA, LLC | $17.84 | 2024 | Amyvid |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Reiman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.